Background: To develop and validate a method for estimating hypoglycemia risk in stable, insulin-treated subjects with type 2 diabetes mellitus.
H
YPOGLYCEMIA IS A POTENtial complication of intensive insulin therapy for type 2 diabetes mellitus. 1, 2 Repetitive or severe episodes may lead to reducing insulin doses, changing insulin preparations, increasing the frequency of self-monitoring of blood glucose (SMBG), modifying target levels for hemoglobin A 1c (HbA 1c ), or changing dietary or exercise behaviors. However, patients with type 2 diabetes may not necessarily report hypoglycemic symptoms or capture hypoglycemic readings on routine monitoring. Many elderly patients have limited knowledge about the manifestations of hypoglycemia, 3 are unable to perceive hypoglycemic symptoms, or develop impairment of psychomotor function when their blood glucose levels decline. 4 Other patients may have comorbidities that impair their memories. Additionally, most insulin-treated patients with type 2 diabetes routinely monitor their blood glucose less than once daily. 5 Consequently, health care providers may need additional information to identify patients at increased risk for hypoglycemia.
Recent studies have shown that parameters derived from blood glucose monitoring are useful for predicting hypoglycemia in patients with type 1 diabetes. [6] [7] [8] [9] The variability of blood glucose levels 6, 7 and the low blood glucose index (LBGI) 6, 8, 9 are strongly correlated with the number of severe hypoglycemic events on longterm follow-up. However, there is limited information about the use of SMBG data for assessing the risk of hypoglycemia in patients with type 2 diabetes. It is also unclear if more convenient measures of treatment intensity such as HbA 1c are suitable for this purpose.
The Diabetes Outcomes in Veterans Study (DOVES) is a prospective, observa-
ORIGINAL INVESTIGATION
From the New Mexico VA Health Care System (Drs Murata and Hoffman) tional study of risk factor control in stable, insulintreated veterans with type 2 diabetes mellitus. 10 For part of the study, sequential patients were asked to do SMBG before meals and at bedtime for 8 weeks. Analysis of these data showed that the risks of hypoglycemia and hyperglycemia varied substantially with the time of day 11 and that SMBG resulted in significant improvements in HbA 1c levels even in the absence of a structured intervention. 12 The purpose of this study was to determine if the glucose data obtained by these subjects during the intensive monitoring protocol could be used to identify those at risk for hypoglycemia in the following year when subjects were measuring their blood glucose levels ad libitum. Using SMBG for this purpose requires a theoretical construct in which multiple readings are reduced to parameters that express this risk. Our approach was based on the premise that an individual's risk of hypoglycemia is a function of his or her mean blood glucose level and its standard deviation. The mean blood glucose reflects the intensity of glycemic control. The standard deviation summarizes the effects of a variety of physiologic and behavioral factors that contribute to glucose variability. The likelihood that any reading will fall below a critical value is increased if the mean glucose is low or its standard deviation is high. This strategy decomposes the risk of hypoglycemia into 2 components that might be targeted by different strategies to minimize its frequency. For example, if this concept is valid, then the increased risk of hypoglycemia caused by intensive glycemic control might be offset by strategies that reduce glucose variability. This concept can be validated by showing that a multivariate model comprised of mean blood glucose and its standard deviation can identify patients with different rates of hypoglycemia in the future. We used a splitsample method in which the model was developed in one randomly selected cohort and then validated in an independent sample followed for up to 1 year.
METHODS

PATIENTS
Potential subjects were identified from computer pharmacy records at the New Mexico VA Health Care System, the Carl T. Hayden VA Medical Center, and the Southern Arizona VA Health Care System. Candidates were randomly sampled using microcomputer-generated random numbers. Patients were eligible for this study if they developed diabetes after the age of 35 years, had no history of diabetic ketoacidosis, took at least 1 injection of a long-acting insulin preparation daily, and did not self-titrate their insulin doses. They were excluded if they had a history of alcoholism or other substance abuse; had chronic liver disease, pancreatic insufficiency, a chronic infectious disease, or an endocrinopathy associated with abnormal glucose homeostasis; had a most recent creatinine value of greater than 3.0 mg/dL (264 µmol/L); received glucocorticoids or immunosuppressive drugs; were being treated with an insulin pump; or had a life-expectancy of less than 1 year.
Eligible subjects were required to have stable diabetes for at least 2 months. Diabetes was considered stable if (1) the daily insulin dose was increased by no more than 10 U or 15% of the baseline dose, whichever was smaller; (2) no new oral medications were prescribed; and (3) the dose of established oral medications was not increased. At entry, subjects completed questionnaires on their disease complications, disabilities, physical activities, treatment regimens, and dietary habits. We also measured height, weight, and HbA 1c . A Tosoh (Grove City, Ohio) high-performance liquid chromatography method was used at each study site to measure HbA 1c .
Research coordinators trained subjects to correctly use a glucose test meter and observed them taking readings until they could generate reproducible results. The first 218 subjects enrolled in this study were instructed to measure blood glucose levels before breakfast, before lunch, before dinner, and at bedtime for 8 weeks. Subjects returned to the coordinator at 4 and 8 weeks to have their glucose test meters downloaded and provide blood samples for HbA 1c . GLUMEAN refers to the mean blood glucose for the 8-week period, while GLUSD refers to the 8-week glucose standard deviation.
After completing this protocol, subjects resumed testing their blood glucose levels in their customary manner. Blood glucose readings were obtained with Comfort Curve test strips and an electronic blood glucose test meter (AccuChek Complete, Roche Diagnostics, Indianapolis, Ind) capable of storing 1000 readings and their dates and times. Subjects made follow-up visits to the research coordinators at 26, 39, and 52 weeks. At these visits, research coordinators observed subjects performing SMBG, identified all hypoglycemic events captured by the glucose test meters, and measured HbA 1c . Hypoglycemia was defined as a blood glucose level of 60 mg/dL or less (Յ3.33 mmol/L). During follow-up, research personnel made no recommendations or referrals regarding diabetes management and deferred all treatment decisions to the primary care provider. However, investigators notified the primary care provider immediately for all emergency findings.
Informed consent was obtained from all subjects. This protocol, which covered both the initial evaluation and follow-up period, was approved by the institutional review boards at the participating medical centers.
STATISTICAL ANALYSIS
The principal hypothesis for this study was that the risk of hypoglycemia could be expressed as a function of mean blood glucose and its variability. The SMBG data were used to develop and validate a multivariate model for estimating their contributions to this risk. Computer-generated random numbers were used to assign approximately 40% of subjects to a derivation set and 60% to a validation set.
Model Derivation
Each subject in the derivation set was assigned to 1 of 3 groups based on the number of hypoglycemic events observed during the 8 weeks of intensified SMBG. The first group (group 0) comprised those who did not develop hypoglycemia. The remaining patients were divided into 2 groups depending on whether the number of events was less than or equal to (group 1) or greater than (group 2) the median number of hypoglycemic events in patients who developed hypoglycemia. This classification was necessary because the skewed distribution of hypoglycemic events made it unsuitable for use as a dependent variable in multiple linear regression. The groupings represented a ranking of subjects by hypoglycemia frequency. The group number was therefore treated as an ordinal variable.
Polychotomous logistic regression for an ordinal dependent variable was used to examine the effect of the glucose parameters on group membership. 13 The dependent variable was the group number. The candidate predictor variables were GLUMEAN and GLUSD. The output of this analysis was the probability of membership in all groups exceeding each level of the grouping variable. Because there were 3 such levels (0, 1, and 2), the procedure generated 2 probabilities-the probability of belonging to a group Ͼ0 [P(groupϾ0)] and the probability of belonging to a group Ͼ1 [P(groupϾ1)]. Note that P(groupϾ0) was the probability of developing at least one episode of hypoglycemia during the 8 weeks of intensified monitoring, whereas P(groupϾ1) was the probability of developing hypoglycemia at a rate exceeding the median frequency.
GLUMEAN and GLUSD were incorporated into the model by a forward-stepping procedure with an ␣ Յ.05 to enter. The degree of improvement with each step was analyzed by the improvement 2 test, a method that examines the statistical significance of the change in log likelihood. In polychotomous logistic regression, the probability of group membership greater than any level is always a function of the same linear combination of GLUMEAN and GLUSD. P(groupϾ0) was given by the expression e u0 /(1 + e u0 ), where u 0 = constant 0 + k GLUMEAN ϫ GLUMEAN + k GLUSD ϫ GLUSD. P(groupϾ1) was given by the expression e u1 /(1 + e u1 ), where
Note that the terms u 0 and u 1 were identical except for their constants. Polychotomous logistic regression generated estimates for the constants, k GLUMEAN and k GLUSD . The independent variables were considered statistically significant if the 95% confidence intervals (CIs) for their odds ratios did not include 1.
Model Validation
Once the models were developed, it was possible to assign a predicted probability of group membership for each patient in the validation set. These predicted probabilities were calculated by substituting the subject's GLUMEAN and GLUSD into the expressions for P(groupϾ0) and P(groupϾ1) developed from the derivation sample. We hypothesized that the predicted probability of developing hypoglycemia during 8 weeks of intensified SMBG [P(groupϾ0)] reflected the patient's risk of hypoglycemia on long-term follow-up ("long-term hypoglycemia"). To test this hypothesis, we used P(groupϾ0) to stratify validation subjects into 4 quartiles of risk. Differences in the occurrence of long-term hypoglycemia across risk strata were tested by 2 analysis. We also hypothesized that the predicted probability of developing hypoglycemia at a rate exceeding the median value during intensified SMBG [P(groupϾ1)] was predictive of long-term hypoglycemia at a rate exceeding the median value ("long-term, high-frequency hypoglycemia"). To test this hypothesis, we used P(groupϾ1) to stratify subjects into quartiles and tested differences in the occurrence of long-term, highfrequency hypoglycemia by 2 analysis. We compared P(groupϾ0) and HbA 1c for their ability to identify patients at risk for long-term hypoglycemia. Because they were continuous variables, the most appropriate method was a receiver operating characteristic (ROC) curve analysis.
14 This analysis calculated the proportions of true positives and false positives as the cut point for a "positive" test was varied across the range of values for the predictor variable. The ROC curve was generated by plotting true-positive vs falsepositive rates. The area under the ROC curve measured whether the predictor distinguished subjects who developed longterm hypoglycemia from those who did not. A perfect predictor will have an area under the ROC curve of 1.0, while a predictor with no discriminating ability will have an area of 0.5. The standard error (SE) for the ROC curve area was calculated by the method of Hanley and McNeil. 14 The difference in the ROC curve areas for P(groupϾ0) and HbA 1c was considered statistically significant if their 95% CIs did not overlap. The 95% CI for the ROC curve area was considered the mean value ± 1.96 SE. The analysis was repeated to determine if P(groupϾ1) and HbA 1c were able to identify patients at risk for long-term, high-frequency hypoglycemia.
All results are reported as mean ± SD. PϽ.05 was considered statistically significant.
RESULTS
We enrolled 218 subjects in the study. Eight withdrew from the intensified monitoring protocol after initially consenting, and 15 were lost to follow-up. Seventy-two (36.9%) of the remaining 195 subjects were randomly assigned to the derivation set, while 123 (63.1%) were assigned to the validation set.
MODEL DERIVATION
The mean age of the derivation subjects was 65.0±9.8 years, 11.1% were women, and 26.8% were members of a racial or ethnic minority. The mean body mass index (calculated as weight in kilograms divided by the square of height in meters) was 32.0±5.7, the amount of exercise averaged 55.7±59.0 metabolic equivalent task (MET)-hours per week, and the entry HbA 1c was 7.79%±1.35%. Thirty-two percent of patients were taking oral hypoglycemic agents, and the mean dose of insulin was 63.5±39.2 U/d. Subjects were asked how many times they had had a low blood glucose value associated with sweating, weakness, anxiety, trembling, hunger, or headache in the month before study entry. Responses were grouped into 5 categories: 31 reported no episodes, 25 reported 1 to 3 episodes, 8 reported 4 to 6 episodes, 2 reported 7 to 12 episodes, and 2 reported more than 12 episodes. Four subjects did not answer this question.
During the 8 weeks of intensified monitoring, the mean blood glucose value was 181±41 mg/dL (10.0±2.28 mmol/L), and the glucose standard deviation was 65±20 mg/dL (3.61±1.11 mmol/L). Sixty-one subjects missed no more than 3 consecutive days of readings. In this group, there was little variation in the weekly glucose mean (range, 175 mg/dL [9.71 mmol/L] to 180 mg/dL [9.99 mmol/L]) or in the weekly glucose standard deviation (range, 57 mg/dL [3.16 mmol/L] to 62 mg/dL [3.44 mmol/L]). For this reason, the 8-week glucose mean (GLUMEAN) and standard deviation (GLUSD) were used for model derivation. Hypoglycemia was detected in 36 subjects (50.0%). The median number of events among the hypoglycemic subjects was 2.5 (interquartile range, 2-5). Kruskal-Wallis one-way analysis of variance by ranks showed that the number of events detected during intensified monitoring was only marginally different (P=.07) across the groups that had reported different hypoglycemia rates at entry. Subjects who became hypoglycemic had a significantly lower 8-week mean blood glucose level (166 ± 31 mg/dL [9.21 ± 1.72 mmol/L] vs 197 ± 45 mg/dL [10.9 ± 2.50 mmol/L]; P = .001). However, no differences were found in glucose standard deviation (64±21 mg/dL [3.55±1.17 mmol/L] vs 67±21 mg/dL [3.72 ± 1.17 mmol/L], respectively; P = .61). GLUMEAN was negatively correlated with the number of blood glucose readings taken during intensified monitoring (r=−0.388; P=.002), but no relationship was found for GLUSD. The 36 subjects who did not develop hypoglycemia during intensified SMBG were assigned to group 0, 18 who had 2 or fewer episodes were assigned to group 1, and 18 who developed more than 2 episodes were assigned to group 2.
Polychotomous logistic regression showed that both GLUMEAN and GLUSD were highly influential determinants of group membership (Table) . Both variables resulted in significant improvement in the logistic model (improvement 2 PϽ.001) and had adjusted odds ratios significantly different from 1. A low mean glucose and a large glucose standard deviation increased both the risk of hypoglycemia during intensified SMBG and the likelihood that the observed rate would exceed the median value.
MODEL VALIDATION
The mean age of the 123 subjects in the validation set was 64.8±10.0 years, 1.6% were women, and 32.8% were members of a racial or ethnic minority group. The mean body mass index was 31.7 ± 5.9, the amount of exercise averaged 65.6± 61.5 MET-hours per week, and the entry HbA 1c was 8.24%±1.81%. Forty-one percent were taking oral hypoglycemic agents, and the mean dosage of insulin was 64.4 ± 45.4 U/d. During 8 weeks of intensified monitoring, their mean blood glucose was 176±41 mg/dL (9.77±2.28 mmol/L), and their glucose standard deviation was 62 ± 19 mg/dL (3.44 ± 1.05 mmol/L). For each subject, the expressions shown in the Table were used to calculate a predicted probability of hypoglycemia [P(groupϾ0)] and a predicted probability of hypoglycemia at a rate exceeding the median value [P(groupϾ1)]. P(groupϾ0) was used to stratify the validation set into quartiles; the cut points for this classification were 0.310, 0.545, and 0.769. The process was repeated using P(groupϾ1). These cut points were 0.084, 0.197, and 0.406.
After completing the intensified monitoring protocol, subjects were followed up for a mean of 39.7±7.1 weeks. During this time, 60 (48.8%) developed hypoglycemia. The median rate of long-term hypoglycemia for these subjects was 0.570 events per 4 weeks (interquartile range, 0.190-1.14). The 28 subjects with hypoglycemia rates exceeding 0.570 events per 4 weeks were considered to have "long-term, high-frequency hypoglycemia."
There were highly significant differences in the occurrence of long-term hypoglycemia across quartiles defined by P(groupϾ0). These proportions were 19.4%, 36.7%, 61.3%, and 77.4%, respectively (PϽ.001). The ROC curve analysis showed that P(groupϾ0) successfully distinguished subjects who eventually developed long-term hypoglycemia from those who did not (area=0.746±0.046). However, the ROC curve area for HbA 1c (0.549±0.052) was not significantly different from 0.5 and therefore had no prognostic value.
The logistic model also identified subjects who would eventually develop long-term, high-frequency hypoglycemia. The proportions of subjects with this complication in the quartiles defined by P(groupϾ1) were 0%, 10.0%, 32.3%, and 48.4% (PϽ.001). The ROC area for P(groupϾ1) was 0.813±0.039, a value significantly greater than the ROC area for HbA 1c (0.540±0.061). Again, the HbA 1c test failed to identify subjects who would develop hypoglycemia exceeding the median frequency.
We also evaluated whether the model could still accurately predict hypoglycemic risk using fewer glucose readings. This analysis was important because 8 weeks of intensified monitoring is impractical for most patients. A total of 119 subjects in the validation set obtained glucose readings for 4 or more days in the first week of intensified monitoring. The mean number obtained was 23.4±5.2. For each of these subjects, GLUMEAN and GLUSD were derived from these data and used in the expressions shown in the Table to recalculate individual estimates for P(groupϾ0) and P(groupϾ1). The cohort was then stratified by each calculated probability into 4 quartiles of risk. On long-term follow-up (mean, 39.8±6.8 weeks), there were highly significant differences in the occurrence of long-term hypoglycemia from the lowest to highest quartile defined by P(groupϾ0) (33.3%, 30.0%, 55.2%, and 76.7%, respectively; P=.001). Likewise, there were significant differences in the occurrence of longterm, high-frequency hypoglycemia across quartiles defined by P(groupϾ1) (12.9%, 13.8%, 24.1%, and 40.0%, respectively; P=.04).
COMMENT
The risk of hypoglycemia increases when the treatment of type 2 diabetes is intensified 1,2 and can pose a significant impediment to achieving glycemic targets. It is unclear how this increased risk should be managed. We hypothesized that the probability of developing hypoglycemia depends on the mean blood glucose level and the tendency of individual readings to deviate from this mean. Thus, hypoglycemia is more likely if the mean blood glucose is low or if negative deviations from the mean are large. If this concept is valid, then mean glucose and its standard deviation should be independent determinants of hypoglycemia on multivariate analysis. We further assumed that the risk attributable to these 2 parameters was an enduring attribute in stable patients that would affect the frequency of hypoglycemia on longterm follow-up. Both of these concepts were validated in this study. Thus, the risk of hypoglycemia appears to be unique to each subject, is stable for up to 1 year, and is as much due to glucose variability as the mean glucose Abbreviations: CI, confidence interval; GLUMEAN, 8-week mean blood glucose level; GLUSD, standard deviation of GLUMEAN.
*The probability of membership in a group Ͼ0 [P (group Ͼ0)] is given by the expression e u0 /(1 + e u0 ), where u 0 = 4.61 − 0.0639ϫGLUMEAN + 0.108 ϫ GLUSD. †The probability of membership in a group Ͼ1 [P (group Ͼ1)] is given by the expression e u1 /(1+e u1 ), where u 1 = 3.03 − 0.0639 ϫ GLUMEAN + 0.108 ϫ GLUSD.
level. In addition, this risk can be ascertained with a single week of intensified blood glucose monitoring as long as readings are obtained before meals and at bedtime. Finally, the validation patients were treated by their health care providers in the customary fashion. On long-term follow-up, 24.4% had their oral hypoglycemic agents changed and 97.6% had their insulin preparations switched or insulin doses adjusted. The fact that the model was able to predict hypoglycemic events in subjects on constantly varying treatment regimens suggests that the method is quite robust and minimally affected by treatment changes that occur in routine practice.
Modeling of hypoglycemia risk based on glucose kinetics has certain advantages because the functions provide a method for estimating the risk for different combinations of the glucose variables. For example, our model shows that the estimated risk for at least 1 episode of hypoglycemia in 8 weeks of intensified monitoring is 6% for a subject with a mean glucose of 200 mg/dL (11.1 mmol/L) and a standard deviation of 50 mg/dL (2.78 mmol/L). This risk increases to 60% for a subject with a mean glucose value of 150 mg/dL (8.33 mmol/L) and the same standard deviation but returns to 6% in a patient with a mean glucose value of 150 mg/dL (8.33 mmol/L) and a standard deviation of 20.5 mg/dL (1.14 mmol/L). This analysis suggests that minimizing glucose variability is a plausible method for offsetting the increased risk of hypoglycemia associated with tight glycemic control. However, the method describes changes in hypoglycemia risk from patient to patient as a function of their glucose parameters. It should not be used to forecast a change in the risk within an individual when his or her GLUMEAN or GLUSD is modified.
It seems obvious that patients who are tightly controlled would have a higher risk of hypoglycemia in the future. However, in type 1 diabetes, it has been difficult to demonstrate that HbA 1c is an indicator of this risk. 6, 8 The present study suggests that self-measured blood glucose is a much better predictor of future hypoglycemic events than HbA 1c . In addition, a large variation in blood glucose was an independent risk factor that can be ascertained only by frequent blood glucose monitoring. Our study shows that, although HbA 1c is the standard measure for glycemic control, it cannot substitute for intensified SMBG in identifying patients who will develop hypoglycemia in the future.
The hypoglycemia risk associated with large fluctuations in blood glucose levels has important clinical implications. This finding suggests that clinicians should attempt to reduce glucose variations attributable to dietary irregularities, mismatching of caloric intake and insulin therapy, medication noncompliance, or exercise during treatment intensification. This concept was exemplified by a randomized clinical trial comparing implantable insulin pumps to multiple daily insulin injections in subjects with type 2 diabetes. 15 A reduction in glucose variability achieved by the former method resulted in a significant reduction in the incidence of mild, clinical hypoglycemia. Future studies should be done to validate the concept that reducing glucose variability mitigates the higher rates of hypoglycemia associated with treatment intensification. It should also be noted that our study established GLUMEAN as a predictor, but not necessarily a cause, of hypoglycemia. This distinction is important because the relationship between these 2 variables might have been confounded by certain patient behaviors. For example, a low glucose mean and a high rate of hypoglycemia could be separate manifestations of excessive dieting or exercise. This possibility is supported by our finding that the lowest mean glucose values were found in the patients who were most compliant with our intensive monitoring protocol. Accordingly, we believe that a low mean glucose value in a patient with hypoglycemia should prompt a search for high-risk behaviors. It remains to be proven that allowing the mean glucose level to drift upward will decrease the hypoglycemia rate.
Several studies have shown that parameters derived from glucose monitoring are useful for evaluating the risk of hypoglycemia in type 1 diabetes. 6, 8, 9 The LBGI is derived from low blood glucose readings obtained during routine monitoring. The risk attributable to a single low reading is quantified by logarithmically transforming and quadratically weighting the raw value. The LBGI is the sum of the risks for the low readings divided by the total number of readings. Cox et al 6 showed that the LBGI and blood glucose standard deviation, but not HbA 1c , were independent predictors of severe hypoglycemia on multivariate analysis. In a larger cohort, this group identified thresholds for LBGI for which there were stepped increases in the odds ratio for future events. 8 Only the LBGI and a history of severe hypoglycemia were identified as independent risk factors. Finally, a prospective study 9 showed that the LBGI rose, mean blood glucose declined, and blood glucose variance increased in the 24 hours before a hypoglycemic episode. These parameters normalized within 48 hours.
There are significant differences between the LBGI and the probability functions reported in this study. The LBGI was validated against the number of hypoglycemic episodes, while our method was used to stratify patients into risk groups. The end point in the LBGI studies was severe hypoglycemia, while our study used hypoglycemia of any severity. The expressions in this study used all glucose readings obtained from the monitoring protocol and incorporated glucose variability. The LBGI is derived from readings below the midpoint of an acceptable range for blood glucose. Finally, our functions are not based on transformed and weighted data. Nevertheless, both studies show that blood glucose readings from a standardized monitoring protocol are extremely useful for determining the risk of hypoglycemia on long-term follow-up.
Because of our population, our conclusions cannot be extrapolated to women, younger patients, nonveterans, or those taking only oral hypoglycemic agents. In addition, the mechanisms of hypoglycemia may differ for patients who have unstable diabetes, are undergoing treatment intensification, or have comorbidities affecting glucose homeostasis such as chronic liver or renal disease.
In summary, intensified SMBG prospectively identified patients at risk for hypoglycemia and those with an excessive hypoglycemia rate on long-term follow-up. This risk was increased by a low mean blood glucose level or large (REPRINTED) ARCH INTERN MED/ VOL 164, JULY 12, 2004 glucose standard deviation and could be expressed as a logistic function involving the 2 parameters. Because the risk associated with lowering mean blood glucose level cannot be avoided during aggressive insulin treatment, clinicians should attempt to reduce glucose variability attributable to behavioral and physiologic factors. Future studies should be done to confirm that periodic intensified SMBG can reduce the risk of hypoglycemia in insulin-treated veterans with type 2 diabetes. 
